Drug Profile
Research programme: cancer vaccines - Immunomic Therapeutics
Latest Information Update: 28 Jun 2021
Price :
$50
*
At a glance
- Originator Immunomic Therapeutics
- Class Cancer vaccines; Dendritic cell vaccines; DNA vaccines
- Mechanism of Action CD4-positive T lymphocyte stimulants; CD8 positive T lymphocyte stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 29 Mar 2019 Pharmacodynamics data from a preclinical studies in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)
- 15 May 2017 Immunomic Therapeutics has patent protection for cytomegalovirus-targeting cancer vaccines licensed from Annias Therapeutics